Semax

Overview

Semax is a synthetic heptapeptide derived from the N-terminal region of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-7) fragment Met-Glu-His-Phe, to which the tripeptide Pro-Gly-Pro is appended at the C-terminus. The parent ACTH(4-10) sequence had been known since the 1960s to influence learning, attention, and memory in animal models without engaging the hypothalamic-pituitary-adrenal axis or producing corticosteroid effects. The Pro-Gly-Pro extension stabilizes the molecule against aminopeptidases and dipeptidyl peptidases, substantially extending its half-life in plasma and brain tissue.

The peptide was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences under the direction of Ivan Ashmarin and his colleagues, with subsequent characterization led by Nikolai Myasoedov and his research group. Semax has been registered for clinical use in the Russian Federation since 1995 for the treatment of ischemic stroke, optic nerve atrophy, and certain cognitive disorders. It is administered intranasally. Outside Russia, the peptide has not been evaluated by the FDA, EMA, or other major regulatory bodies, and it remains a research compound.

Mechanism of Action

Semax produces a broad set of central nervous system effects through several molecular pathways. The pharmacology is best characterized in the rat brain, where the bulk of the mechanistic literature has been developed.

BDNF and NGF Upregulation

Dolotov and colleagues (2003, 2006) reported sustained upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in rat hippocampus and basal forebrain following Semax administration. Shadrina et al. (2010, Acta Naturae) extended this work using microarray and quantitative PCR analyses, identifying coordinated upregulation of neurotrophin pathway genes alongside immediate early gene activation.

Monoamine Neurotransmission

Levitskaya and colleagues have reported that Semax modulates dopamine and serotonin turnover in the striatum and prefrontal cortex. The effect appears to be indirect, mediated through enkephalin and other endogenous opioid peptide systems rather than direct receptor binding.

Neuroprotection through Anti-Apoptotic Signaling

In models of ischemic injury, Semax administration has been associated with reduced caspase activation, attenuated oxidative stress markers, and decreased infarct volume. The molecular pathway has been proposed to involve the same neurotrophin signaling that underlies the cognitive effects.

Heptapeptide Stability

The Pro-Gly-Pro tail is the structural feature that distinguishes Semax from the inactive ACTH(4-7) parent fragment. Without the extension, the peptide would be cleaved within minutes; with it, plasma and brain concentrations remain detectable for hours after intranasal administration.

Research Summary

Ischemic Stroke

The most consequential clinical record for Semax is in ischemic stroke. Gusev, Skvortsova, and colleagues at the Russian State Medical University have published several stroke trials in Russian neurology journals since 1997, generally reporting improved functional recovery scores in patients treated with Semax compared to controls. Independent Western trials of comparable scale have not been conducted, and the underlying study designs are not always available in the Western evidence-grading literature.

Optic Nerve and Retinal Protection

Polunin and colleagues (2003) reported visual function improvements in patients with optic nerve atrophy treated with Semax, which led to the inclusion of optic nerve indications in the Russian registration. The proposed mechanism centers on neuroprotection of retinal ganglion cells.

Cognitive and Attention-Related Research

Smaller Russian studies have explored Semax in attention disorders, post-concussion syndrome, and age-related cognitive complaints. The literature is less robust than the stroke record, and independent replication is limited.

Research Status

Semax holds Russian marketing authorization but has not been submitted for evaluation by the FDA or EMA. The published clinical literature is concentrated in Russian-language journals with limited Western indexing. Researchers working with the compound outside Russia treat it as a research peptide rather than a therapeutic. The intranasal administration route used in Russian clinical work reflects the peptide’s poor oral bioavailability and the desire to access the central nervous system directly through nasal mucosal pathways.

Dosing in Published Research

Semax is a synthetic peptide that is not approved in the United States or the European Union. It is registered as a medicine in Russia, where it is sold as intranasal drops in 0.1% and 1% strengths. Doses in the Russian product labeling and clinical literature vary by indication and are generally in the range of a few hundred micrograms up to roughly 900 micrograms per day, divided across two or three intranasal administrations. These figures describe registered use within the Russian healthcare system; they have not been evaluated by the FDA.

Frequently Asked Questions